In CKD, SGLT2i reduced the kidney composite outcome when compared to incretin-based therapies (HR 0.82, 95% CI 0.73–0.91) and finerenone (HR 0.81, 95% CI 0.71–0.92), with no significant difference between incretin-based therapies and finerenone (HR 0.99, 95% CI 0.87–1.12). Here, GCG is linked to chronic kidney disease.